By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Proteros Biostructures today said that it has entered into a drug discovery services agreement with the CHDI Foundation, a non-profit scientific organization focused on discovering and developing Huntington's disease therapies.

Under the alliance, Martinsried, Germany-based Proteros will provide structure-based drug discovery services to CHDI using its integrated discovery platform including proprietary X-ray crystallography tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.